- Home
- TCRT vs EVOK Comparison
TCRT vs EVOK Comparison
Compare TCRT & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- EVOK
- Stock Information
- Founded
- TCRT 1998
- EVOK 2007
- Country
- TCRT United States
- EVOK United States
- Employees
- TCRT N/A
- EVOK N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- EVOK Health Care
- Exchange
- TCRT Nasdaq
- EVOK Nasdaq
- Market Cap
- TCRT 5.5M
- EVOK 5.4M
- IPO Year
- TCRT N/A
- EVOK 2013
- Fundamental
- Price
- TCRT N/A
- EVOK N/A
- Analyst Decision
- TCRT
- EVOK
- Analyst Count
- TCRT 0
- EVOK 0
- Target Price
- TCRT N/A
- EVOK N/A
- AVG Volume (30 Days)
- TCRT 47.7K
- EVOK 30.7K
- Earning Date
- TCRT 11-13-2025
- EVOK 11-06-2025
- Dividend Yield
- TCRT N/A
- EVOK N/A
- EPS Growth
- TCRT N/A
- EVOK N/A
- EPS
- TCRT N/A
- EVOK N/A
- Revenue
- TCRT $6,000.00
- EVOK $12,794,859.00
- Revenue This Year
- TCRT $5,680,500.00
- EVOK $57.38
- Revenue Next Year
- TCRT N/A
- EVOK $59.57
- P/E Ratio
- TCRT N/A
- EVOK N/A
- Revenue Growth
- TCRT N/A
- EVOK 70.02
- 52 Week Low
- TCRT $1.31
- EVOK $1.94
- 52 Week High
- TCRT $6.20
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- TCRT 66.77
- EVOK N/A
- Support Level
- TCRT $2.44
- EVOK N/A
- Resistance Level
- TCRT $3.17
- EVOK N/A
- Average True Range (ATR)
- TCRT 0.19
- EVOK 0.00
- MACD
- TCRT 0.06
- EVOK 0.00
- Stochastic Oscillator
- TCRT 81.81
- EVOK 0.00
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.